Eisai Inc.
900 Davis Drive
P.O. Box 14505
Research Triangle Park
North Carolina
27709
United States
Tel: 919-941-6920
Fax: 919-941-6931
Website: http://www.eisai.com/
About Eisai Inc.
Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.
Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com.
186 articles about Eisai Inc.
-
Eisai Inc. And Arena Pharmaceuticals, Inc. Announce Presentation Of Lorcaserin Hcl Data At Upcoming Medical Meetings
5/14/2015
-
Eisai Inc. Launches BELVIQ® VOICES, an Online Community Of Personal Weight Loss Stories, Featuring Real Life Experiences With BELVIQ® (Lorcaserin Hcl) CIV
2/19/2015
-
Eisai Inc. Release: Pivotal Phase 3 Trial of Investigational Agent Lenvatinib In Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer Published In New England Journal Of Medicine
2/12/2015
-
Arena Pharmaceuticals, Inc. Reports On Eisai Inc.'s New Marketing Initiatives For BELVIQ® (lorcaserin HCl) CIV
1/9/2015
-
Oncodesign SA Has Entered Into A Services Agreement With Eisai Inc. To Develop A New Personalized Medicine Program In Earlier Line Metastatic Breast Cancer Treatment
12/17/2014
-
Eisai Inc.'s David Martin Elected As National Pharmaceutical Council's Chairman Of The Board
11/7/2014
-
Eisai Inc. Announces FDA Acceptance Of Supplemental New Drug Application For Antiepileptic Drug Perampanel As Adjunctive Treatment Of Primary Generalized Tonic-Clonic Seizures
10/20/2014
-
Eisai Inc. Launches New Online Resource Helping Women Living With Metastatic Breast Cancer Navigate Their Journey
10/13/2014
-
Eisai Inc. Grabs FDA Approval For Chemotherapy Side Effect Drug AKYNZEO®
10/13/2014
-
FDA Approves Eisai Inc. Drug For Chemotherapy-Associated Nausea
10/10/2014
-
Results Of Eisai Inc. And Epilepsy Foundation National Survey Shed Light On Unmet Needs In Epilepsy Community
10/1/2014
-
Eisai Inc. And Arena Pharmaceuticals, Inc. Announce BELVIQ® (lorcaserin HCl) CIV Nominated A Second Time For The Prix Galien Award In The Best Pharmaceutical Agent Category
7/29/2014
-
Eisai Inc. & Helsinn Group To Present New CINV Research At 2014 International Symposium On Supportive Care In Cancer
6/26/2014
-
Barry Lederman Appointed Vice President And Chief Financial Officer Of Eisai Inc.
6/23/2014
-
Eisai Inc.'s Antiepileptic Drug Perampanel Meets Primary Endpoint In Phase 3 Study
6/16/2014
-
Eisai Inc. Sponsors The Epilepsy Foundation Of Metropolitan New York's 2nd Annual Epilepsy Awareness Day At Citi Field
6/13/2014
-
Eisai Inc.'s New Thyroid Cancer Drug Lenvatinib Shows Promise In Phase 3 Study
6/2/2014
-
Eisai Inc. Launches National Television Advertising Campaign For BELVIQ® (lorcaserin HCl) CIV
4/14/2014
-
Otsuka Pharmaceutical Co., Ltd. Acquires Rights To Hematological Cancer Treatment Dacogen® From Eisai Inc. (U.S.)
3/31/2014
-
Eisai Inc.'s President And CEO To Retire
3/10/2014